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ABSTRACT
Background: Severity of hepatocellular carcinoma (HCC) that is assessed using barcelona clinic liver cancer 
(BCLC) classification is a main prognostic factor of hepatocellular carcinoma. Assessment of the serum level of 
vascular endothelial growth factor (VEGF) is considered to reflect the severity of HCC. However, there is still 
no fundamental basis of the association of severity of HCC with the serum VEGF level. The objective of this 
study is to know the relationship between serum VEGF levels with the severity of HCC by assessing the average 
difference of serum VEGF level in various severity of HCC.
Method: This study was a cross sectional study to identify the association between serum VEGF levels with 
the severity of HCC based on BCLC classification. This study was performed in Cipto Mangunkusumo Hospital 
between January and May 2015. Statistical tests used to evaluate the association between serum VEGF level 
with BCLC classification was one-way ANOVA analysis, and continued with post hoc Tukey Schaffe analysis.
Results: A total of 61 subjects with HCC were included into this study. In this study, we did not find subjects 
with stage 0 BCLC. The average of serum VEGF level in stage A BCLC was 288.26 ± 156.6 pg/mL; stage B 
BCLC: 434 ± 164.8 pg/mL; stage C BCLC: 785.57 ± 194.25 pg/mL; stage D BCLC: 1537.97 ± 660.62 pg/
mL. One-way ANOVA analysis showed significant difference (P < 0.001) between serum VEGF level and HCC 
severity based on BCLC classification. Post hoc Tukey Schaffe analysis showed the presence of significant 
difference between stage A and C BCLC (p < 0.05) and stage A and D BCLC (p < 0.001), stage B and D BCLC 
(p < 0.001), and stage C and D BCLC (p < 0.001). There was no significant difference between stage A and B 
BCLC, and between stage B and C BCLC. 
Conclusion: It was found that serum VEGF level increased in accordance to the HCC severity based on 
BCLC classification, particularly for stage B BCLC and above.
Keywords: vascular endothelial growth factor (VEGF), hepatocellular carcinoma (HCC) severity, barcelona 
clinic liver cancer (BCLC).
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ABSTRAK
Latar belakang: Derajat keparahan karsinoma hepatoselular (KHS) yang dinilai dengan klasifikasi barcelona 
clinic liver cancer (BCLC) merupakan faktor prognostik utama KHS. Penilaian kadar serum vascular endothelial 
growth factor (VEGF) dianggap dapat mencerminkan tingkat keparahan KHS. Namun, belum ada landasan 
mengenai hubungan tingkat keparahan KHS dengan kadar serum VEGF. Tujuan penelitian ini adalah untuk 
mengetahui hubungan kadar serum VEGF dengan tingkat keparahan KHS dengan menilai perbedaan rerata 
kadar serum VEGF pada berbagai tingkat keparahan KHS.
Metode: Penelitian ini adalah studi potong lintang untuk menentukan hubungan antara kadar serum VEGF 
dengan tingkat keparahan KHS berdasarkan klasifikasi BCLC. Penelitian ini dilakukan di Rumah Sakit Cipto 
Mangunkusumo antara bulan Januari 2015 dan Mei 2015. Uji statistik yang digunakan untuk menilai hubungan 
kadar serum VEGF dengan klasifikasi BCLC ialah analisis one-way ANOVA, dan dilanjutkan dengan analisis 
post hoc Tukey Schaffe.
Hasil: Sebanyak 61 subyek KHS diikutkan dalam penelitian ini. Pada penelitian ini tidak ditemukan subyek 
dengan BCLC stage 0. Rerata kadar serum VEGF BCLC stage A adalah 288,26 ± 156,6 pg/mL; BCLC stage B: 
434 ± 164,8 pg/mL; BCLC stage C: 785,57 ± 194,25 pg/mL; BCLC stage D: 1537,97 ± 660,62 pg/mL. Analisis 
one-way ANOVA menunjukkan perbedaan bermakna (p < 0,001) antara kadar serum VEGF dengan tingkat 
keparahan KHS berdasarkan klasifikasi BCLC. Analisis post hoc dengan Tukey Schaffe menunjukkan adanya 
perbedaan bermakna antara BCLC stage A dan C (p < 0 ,05) serta BCLC stage A dan D (p < 0.001), BCLC 
stage B dan D (p < 0.001), dan BCLC stage C dan D (p < 0.001). Tidak ditemukan perbedaan bermakna antara 
subyek dengan BCLC stage A dan B, dan antara BCLC stage B dan C.
Simpulan: Didapatkan kadar serum VEGF yang meningkat sesuai dengan tingkat keparahan KHS 
berdasarkan klasifikasi BCLC terutama untuk BCLC stage B ke atas.
Kata kunci: Vascular endothelial growth factor (VEGF), keparahan karsinoma hepatoselular (KHS), 
barcelona clinic liver cancer (BCLC).
INTRODUCTION
Hepatocellular carcinoma (HCC) is the most severe 
primary liver cancer deriving from hepatocytes. Of 
all diagnosed liver tumour, 85% is HCC and 15% is 
other tumours.1 This primary liver cancer ranks sixth 
as the most common malignancy in the world and 
ranks second as the cause of death with more than one 
million case fatalities per year.2,3 Approximately 70-
80% patients with HCC have background of chronic 
liver disease, even those who suffer from HBV and 
HCV have risk of developing HCC 15 times and 17 
times higher, respectively.4,5
The main prognostic factors of HCC are clinical 
pathological characteristics of the disease, which 
include HCC tumour size and degree of severity. One 
of the HCC staging classifications, which is commonly 
used, is staging by barcelona clinic liver cancer 
(BCLC).5,6 BCLC classification besides using Child-
Turcotte-Pugh classification to identify liver function, 
also use tumour size and portal vein thrombosis 
criteria to reveal more accurate results. American 
Association for the Study of Liver Diseases (AASLD) 
and European Association for the Study of the Liver 
(EASL) have agreed the use of BCLC classification as a 
common staging system.2,6,7 The status of performance, 
tumour size, metastasis, ascites, albumin and bilirubin 
level, prothrombin time, and portal vein thrombosis 
are the components used to evaluate the severity of 
HCC. Therefore, it is necessary to have an examination 
modality which could describe of staging or HCC 
severity rapidly.5,6
HCC is a tumour with high vascularisation which 
involves the expression of vascular endothelial 
growth factor (VEGF). VEGF plays role in tumour 
angiogenesis. VEGF expression in tumour cells 
is stimulated by hypoxia, oncogene (race), and 
inactivation of tumour suppressor gene (p53), and 
various cytokines. Activation of VEGF/VEGF 
receptor (VEGFR) stimulates mitogenesis, migration, 
differentiation, and vascular permeability, also 
mobilization of endothelial progenitor cells from the 
bone marrow to the peripheral circulation. VEGF 
activates endothelial cells through the effect of 
endothelial cells morphology changes, cytoskeleton 
changes, and stimulate the migration and growth of 
endothelial cells.8,9
Several studies have evaluated whether the level of 
serum VEGF could be a prognostic factor for survival 
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prognostic in HCC patients. A meta-analysis study 
involving 16 studies showed the role of VEGF that 
was statistically significant towards the survival in 
general and disease-free survival in HCC, and that is 
correlated with the poor prognosis. 9,10,11 Whether the 
level of VEGF is also associated with HCC severity as 
one of the main prognostic factors of HCC still need 
further studies. Examination of VEGF level is expected 
to be able to be marker of HCC severity in the future.
METHOD
This study was a cross sectional study to identify the 
association between VEGF with HCC severity based 
on BCLC classification. This study was performed in 
Hepatobiliary Division Polyclinic and Internal Medicine 
Inpatients Ward Cipto Mangunkusumo Hospital, 
Jakarta, as a national referral hospital in Indonesia. Study 
was performed from January to May 2015.
Study subjects were HCC patients aged more 
than 18 years old who visited Cipto Mangunkusumo 
Hospital during the study period. Sample was obtained 
through non-probability consecutive sampling method. 
Exclusion criteria were hepatic encephalopathy stage 
III and IV, severe sepsis, kidney failure, heart failure, 
presence of other tumour besides in the liver, severe 
hematemesis melena, HCC patients who had received 
curative or palliative management, and other diseases 
which increase the level of VEGF. After HCC diagnosis 
was confirmed, patients’ disease severity was assessed 
using the BCLC criteria. Further, patients had their 
blood drawn for 3.5 cc for VEGF level examination 
in the laboratory.
Data analysis was performed using SPSS 20 for 
windows software. Study results were presented in the 
form of univariate analysis, to describe the distribution of 
component characteristic BCLC classification and VEGF 
level. Statistical tests being used were one-way ANOVA, 
which was further continued with post hoc Tukey Schaffe 
analysis. It was concluded to be significant if we found 
p value < 0.05. This study had received ethical clearance 
from ethical commission of human biomedical research 
Faculty of Medicine University of Indonesia with ethical 
clearance letter No. 28/UN2.F1/ETIK/2014.
RESULTS
This study included 61 subjects with HCC who 
fulfilled inclusion criteria, who further underwent 
VEGF serum sample examination. Subjects consisted 
of 52 males and 9 females with the average age of 55 
± 13 years old. Of overall study subjects, data obtained 
was positive HbsAg in 61% subjects, positive anti-
HCV in 11% subjects, combination of positive HbsAg 
and anti HCV in 2% subjects, and absence of HbsAg 
or anti HCV in 26% subjects. Study subjects who had 
AFP value less than 200 ng/mL were 47%. CT scan 
results revealed study subjects with liver cirrhosis as 
much as 57%. Uninodular tumour was found in 51% 
subjects, while portal vein thrombus was found in 33% 
subjects. Metastasis to the lungs and lymph nodes was 
only found in 2% of study subjects.
Liver function measurement using Child-Turcotte-
Pugh (CP) classification revealed that most subjects 
had CP A classification, which was 49%, while most 
study subjects’ performance status was stage 0, which 
was 39%. HCC severity using BCLC classification 
showed the distribution of subjects with stage A 16%, 
stage B 30%, stage C 20%, and stage D 34%, and no 
stage 0 was found. Complete characteristics of study 
subjects could be seen in Table 1.
Table 1. Characteristics of Study Subjects
Characteristic n (%) mean (SD)
Sex
Male
Female
52 (85.2)
9 (14.8)
Age, years old 55.25  
(SD 13.32)
Hepatitis infection
HBsAg
Anti HCV
HBsAg and anti HCV
Absence of HbsAg or anti HCV
37 (60.7)
7 (11.5)
1 (1.6)
16 (26.2)
AFP
< 200 ng/mL
>200 ng/mL
29 (47.5)
32 (52.5)
Cirrhosis
Yes
No
35 (57.4)
26 (42.6)
Tumour nodularity
Uninodular
Multinodular
31 (50.8)
30 (49.2)
Portal vein thrombus
Yes
No
20 (32.8)
41 (67.2)
Paraaortic lymph node
Yes
No
1 (1.6)
60 (98.4)
Liver metastasis
Yes
No
1 (1.6)
60 (98.4)
Child Turcotte Pugh classification
A
B
C
30 (49.2)
20 (32.8)
11 (18)
Performance status
Stage 0
Stage 1
Stage 2
Stage 3
Stage 4
24 (39.3)
11 (18.0)
8 (13.1)
16 (26.2)
2 (3.3)
BCLC stage
A
B
C
D
10 (16.4)
18 (29.5)
12 (19.7)
21 (34.4)
The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy70
Arles, Rino Alvani Gani, Ari Fahrial Syam, Hamzah Shatri
Based on one-way ANOVA analysis, there was 
a significant different in the average of VEGF level 
based on BCLC classification (p < 0.001). Subjects 
group with stage A BCLC had average VEGF level 
of 288.26 ± 156.6 pg/mL, stage B BCLC group had 
average VEGF level of 434.96 ± 164.8 pg/mL, stage 
C BCLC had average VEGF level of 785.57 ± 194.25 
pg/mL, and stage D BCLC group had average VEGF 
level of 1537.97 ± 660.62 pg/mL. Thus, it could be 
seen that the higher the staging of BCLC, the higher 
the VEGF level. From the post hoc analysis, we found 
significant difference of VEGF level between stage 
A and C BCLC (95% CI: 23.83-964.79), between 
stage A and D BCLC (95% CI: 827.53-1671.88), and 
between stage B and D (95% CI: 750.05-1455.94), 
and stage C and D BCLC (95% CI: 357.76-1153.02). 
This intervariables relationship was shown in Figure 1. 
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Figure 1. Mean differences of serum VEGF level with HCC severity based on BCLC 
classification in the post hoc Tukey Schaffe analysis. 
p<0.001
p<0.05
p<0.001
p<0.001
Figur  1. M a  differ nces of s rum VEGF l vel with HCC 
severity based on BCLC classification in the post hoc Tukey 
Schaffe analysis.
Table 2. VEGF level mean differences from Post Hoc Turkey 
analysis 
Barcelona 
clinic liver 
cancer (BCLC)
Mean 
differences p 95% CI
A B -146.71 0.807 -580.08-286.67
C -494.32 0.036 -964.79 – (-23.83)
D -1249.71 < 0.001 -1671.88 – (-827.53)
B C -347.61 0.123 -757.11 – 61.89
D -1103.00 < 0.001 -1455.94 – (-750.05)
C D -755.39 < 0.001 -1153.02 – (-357.76)
Another finding that was also important to be 
reported in this study was portal vein thrombosis. In 
this study, as much as 20 (32.8%) HCC subjects had 
portal vein thrombosis, with the average serum VEGF 
level of 1048.21 + 741.07 pg/mL. (Table 2).
Table 3. VEGF serum level with or without portal vein thrombosis 
Variable
Portal vein thrombus
Positive  
(n = 20)
Negative  
(n = 41)
Average of VEGF level 
(pg/mL)
1048.21 SD  
(741.07)
766.73 SD  
(603.57)
DISCUSSION
Study results showed that serum VEGF was 
correlated with HCC severity. The high VEGF level is 
also usually found in patients with vascular invasion or 
metastasis, thus this increase indicated poor prognosis 
in HCC patients. Therefore, VEGF has the potential 
to help predicting the occurring tumour differentiation 
and vascular invasion.12,13
Various mechanisms could regulate the expression 
of serum VEGF level in HCC; one of the most 
important mechanisms is hypoxia. Study revealed 
that hypoxia inducible factor-1 (HIF-1) was the main 
mediator in response towards the hypoxia. After being 
released, VEGF would then bind to VEGFR which 
consisted of VEGFR1 and VEGFR2 and further cause 
the activation of VEGF/VEGFR axis which stimulated 
tyrosine kinase pathway.14
Clinical implication of this study results is 
very important because it provides evidence that 
examination of serum VEGF level in HCC which is 
supported by physical examination, liver function 
test, and USG, we can predict the severity of HCC 
based on BCLC classification. Hence, we can plan 
the appropriate further management in HCC patients, 
particularly for internists who work far from referral 
hospital. In this study, we did not find any HCC 
subject with stage 0 BCLC. This happened because 
patients came with the tumour size of more than 2 cm. 
Meanwhile, there were only 10 subjects with initial 
stage (A) BCLC in this study. These findings were 
different from the study performed by Kaseb et al.15 
In 2010, there were a total of 288 subjects, of which 
21 subjects had stage 0 BCLC. 
Other differences were also seen in the cause of 
HCC in this study. The most common cause HCC in 
this study was hepatitis B infection, different from the 
study conducted by Kaseb et al.24 In 2011, the most 
common cause of HCC was hepatitis C infection. 
Percentage of HCC which was complicated by liver 
cirrhosis was not different from this study. Yegin et al in 
2013 stated that HCC often found in later stage, which 
was seen by the high rate of portal vein thrombus or 
even stage C and D based on BCLC classification.16
In this study, there was significant difference 
between the average of serum VEGF level and severity 
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of HCC based on BCLC classification. Serum VEGF 
level increased in accordance to HCC severity based 
on BCLC classification, particularly for stage B and 
above. Further, in post hoc analysis, we found there 
were no significant difference between stage A and B 
and between stage B and C BCLC. There were only 
significant differences in the average of VEGF levels 
between stage A and C, stage A and D, stage B and 
D, and stage C and D. Therefore, we can predict the 
prognosis and further therapy in HCC patients. The 
results of this study was in accordance with the study 
performed by Kaseb et al in 288 HCC subjects, in 
which there was significant difference in serum VEGF 
level in every degree of BCLC classification.15 A study 
conducted by Yegin et al towards 78 HCC subjects 
also revealed that there was no significant difference 
in the serum VEGF level between stage A and B and 
between stage B and C and D, but there was significant 
difference of serum VEGF level between stage A and 
C and D.16
Another study conducted by Abdelbaki et al towards 
40 HCC subjects, with control groups consisted of 40 
healthy individuals and 40 subjects with liver cirrhosis 
in the other group, reported that the results of serum 
VEGF in stage A BCLC was significantly different to 
stage B BCLC, and stage B was significantly different 
towards stage C and D. Additionally, it was also found 
that the higher the classification of BCLC was, the 
higher the serum VEGF level. Significant different 
results were also found in serum VEGF level of HCC 
subjects with liver cirrhosis and healthy individuals.17 
However, this was not in line with the study results 
of Gadelhak et al in their study towards 94 subjects, 
consisting of 67 HCC subjects and 27 cirrhosis subjects. 
In this study, there was no significant difference in 
serum VEGF levels between HCC severities based 
on BCLC classification. This was thought to happen 
because in the study performed by Gadelhak et al, most 
tumours have reached 50% of the liver size.18
Increased serum VEGF level could happen 
as a marker of vascular invasion, metastasis, and 
possibility of tumour recurrence after resection have 
been performed, causing the high serum VEGF level 
as a poor prognosis predictor in HCC. Therefore, the 
serum VEGF level was associated with the low rate of 
survival and disease-free survival.11,12,13
In this study, 20 HCC subjects were found to 
have portal vein thrombus (32.8%), with the average 
of serum VEGF level of 1048.21+741.07 pg/ml. 
Ghonaim et al19 in 2013 conducted a study towards 25 
HCC patients and found 9 (36%) subjects with portal 
vein thrombus with the average serum VEGF level 
of 2300+600 pg/mL. Difference in these results was 
possibly caused by the average larger size of HCC in 
the study conducted by Ghonaim et al.
Based on the results of statistical test above, 
anti-VEGF or VEGFR inhibitor (receptor) seemed 
to be potential to become a treatment of choice in 
HCC with stage B BCLC classification. Sorafenib 
was a monoclonal antibody acting as a tyrosine 
kinase (VGEFR) inhibitor. This drug could be used 
as a monotherapy in HCC or in combination with 
transarterial chemoembolization (TACE) in stage 
B BCLC; other drugs which could be used were 
bevacizumab, a monoclonal antibody that acted as 
an anti-VEGF.7,20 Abdel-Rahman et al performed a 
meta-analysis to 11 studies found that combination 
of TACE and Sorafenib were much better compared 
to monotherapy of TACE or Sorafenib alone. 
Administration of tyrosine kinase inhibitor or anti-
VEGF in patients who received TACE had a vast 
benefits, seen from several cases in which TACE 
had been performed, there were continuous increase 
of VEGF following 7 days post TACE. Because 
the increase of VEGF was a marker of worsening 
condition, sorafenib or bevacizumab was expected 
to be able to suppress VEGF and improved liver 
condition.14,21,22
Limitations of this study were small sample size, 
no stage 0 BCLC was found. The correlation obtained 
was only in one period of time. This is different with 
other studies which included larger sample size and 
found subjects with stage 0 BCLC.
CONCLUSION
We found increased of serum VEGF level in 
accordance with HCC severity based on BCLC 
classification, particularly for stage B BCLC and 
above. Serum VEGF level was associated with HCC 
severity based on BCLC classification. Increased 
serum VEGF level may reveal the poor prognosis in 
HCC patients, therefore holistic and comprehensive 
management are needed.
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